International Forum of Allergy & Rhinology最新文献

{"title":"Limitations of Balloon Sinuplasty in AERD: A Registry-Based Analysis of Clinical Outcomes and Socioeconomic Trends.","authors":"Jamie Rosado Alicea, Francesca M Azevedo, Kathleen M Buchheit, Shravan Asthana, Stella E Lee, Benjamin Bleier, Tanya M Laidlaw, Alan D Workman","doi":"10.1002/alr.70261","DOIUrl":"https://doi.org/10.1002/alr.70261","url":null,"abstract":"<p><strong>Key points: </strong>Balloon sinuplasty in AERD is linked to higher lifetime sinus surgical burden. History of balloon sinuplasty in AERD patients is tied to worse current sinonasal symptoms. Balloon procedure AERD patients resided in more socioeconomically disadvantaged areas.</p>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":" ","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biofilm Exoproteins From Staphylococcus Species Impede Re-Epithelialization of Nasal Epithelial Cells During Wound Healing and Cease Ciliary Beat Frequency","authors":"Sintayehu Ambachew,&nbsp;Mahnaz Ramezanpour,&nbsp;Clare M. Cooksley,&nbsp;Emma F. Barry,&nbsp;Lindsay Durr,&nbsp;Kevin Aaron Fenix,&nbsp;P. J. Wormald,&nbsp;Alkis J. Psaltis,&nbsp;Sarah Vreugde","doi":"10.1002/alr.70146","DOIUrl":"10.1002/alr.70146","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Chronic rhinosinusitis (CRS) is an inflammatory disease with many different contributing factors, including bacterial infection. CRS patients are typically managed with medical therapies; however, these treatments frequently fail, leaving surgery as the only viable option. Despite surgical intervention, patients may experience ongoing clinical manifestations of inflammation and infection, frequently associated with <i>Staphylococcus</i> species colonization. This study explored the influence of <i>Staphylococcus</i> on the wound healing process and ciliary function in vitro.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Exoproteins were extracted from biofilm forms of 15 <i>Staphylococcus</i> isolates obtained from five patients (4 CRS and 1 control patient), each colonized by <i>Staphylococcus aureus, Staphylococcus epidermidis</i>, and <i>Staphylococcus lugdunensis</i>. Human nasal epithelial cells (HNECs) were cultured in monolayers for wound healing assays and at an air–liquid interface (ALI) for ciliary beat frequency measurements. Wound closure, cytotoxicity, interleukin-6 (IL-6), and reactive oxygen species (ROS) release were measured after 30 h post-wound creation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Biofilm exoproteins from all three <i>Staphylococcus</i> species hindered the re-epithelialization of HNECs at 5 and 10 µg/mL with <i>S. aureus</i> exoproteins having significantly stronger effects on impairing wound closure compared to <i>S. lugdunensis</i> exoproteins. <i>S. aureus</i> exerted the most pronounced cytotoxic effect compared to the control. Furthermore, all <i>Staphylococcus</i> species reduced ROS release by HNECs while <i>S. epidermidis</i> and <i>S. lugdunensis</i> induced higher IL-6 levels compared to control. In HNEC-ALI cultures, ciliary beat frequency was significantly reduced by all staphylococci 5 h after application of exoproteins.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Staphylococcal biofilm exoproteins hindered mucociliary function and re-epithelialization of the nasal epithelium, caused cytotoxicity, elicited inflammation, and concurrently reduced ROS release.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"942-955"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Surgical Extent Before Biologic Therapy for CRSwNP","authors":"Alison J. Yu,&nbsp;Kristina A. LaPointe,&nbsp;Kaitlyn Ann Roberts,&nbsp;Michelle Yu,&nbsp;James N. Palmer,&nbsp;Alan D. Workman,&nbsp;Jose L. Mattos,&nbsp;Rodney J. Schlosser,&nbsp;Zachary M. Soler","doi":"10.1002/alr.70220","DOIUrl":"10.1002/alr.70220","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key Points</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>Nearly two-thirds of patients had no surgery or incomplete sinus surgery before biologics.</li>\u0000 \u0000 <li>Among all sinuses, the frontal sinus was the least frequently addressed before biologics.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"1043-1045"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS","authors":"Nicholas J. Campion,&nbsp;Peta-Lee Sacks,&nbsp;Lu Hui Png,&nbsp;Ruoxin Hua,&nbsp;Rhea Darbari Kaul,&nbsp;Raquel Alvarado,&nbsp;Christine Choy,&nbsp;Raymond Sacks,&nbsp;Peter Earls,&nbsp;Raewyn G. Campbell,&nbsp;Larry Kalish,&nbsp;Richard J. Harvey","doi":"10.1002/alr.70166","DOIUrl":"10.1002/alr.70166","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional study was performed on patients with CRSwNP treated with biologics for ≥ 6 months at a tertiary center. All patients had undergone prior sinus surgery, which included a sphenoethmoidectomy and then extension via Draf I, IIa, IIb, IIc, or III. Disease control was defined as having a SNOT-22 ≤ 30, endoscopic modified Lund–Mackay ≤ 4, and the absence of rescue therapy within 6 months. Comparisons were made across surgical and biologic groups, and logistic regression was used to identify factors associated with disease control.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 159 patients were assessed (age 50.9 ± 12.8 years, 45.3% female). Disease control was achieved in 49.1% of patients. Disease control was greater with extended surgery (Draf III 60.8% [49.7%–70.8%] vs. Draf IIc 68.3% [53.0%–80.4%] vs. Draf IIa 8.7% [2.4%–26.8%] vs. Draf I 0% [0.0%–19.4%]; <i>p</i> &lt; 0.001). The control was similar across biologic types (anti-IL-4αR 63.3% [45.5%–78.1%] vs. anti-IL-5/5R 45.7% [37.3%–54.3%]; <i>p</i> = 0.083). On regression, extended surgery (Draf III + IIc) was associated with disease control (Draf III/IIc vs. Draf IIa/I OR: 110.2 [12.7–14,682.5]) but not biologic type (anti-IL-4αR vs. anti-IL-5/5R OR: 2.2 [0.7–7.2]). However, class switching had already occurred in 15.1% of patients initially treated with anti-IL-5/5R.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Disease control was greatest in CRSwNP patients who had both extended sinus surgery and optimized biologic treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"986-995"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recovery of Parosmia Preferentially Influences Longitudinal Improvement of Quality of Life in C19OD","authors":"Tiana M. Saak,&nbsp;Jeremy P. Tervo,&nbsp;Brandon J. Vilarello,&nbsp;Patricia T. Jacobson,&nbsp;Francesco F. Caruana,&nbsp;Liam W. Gallagher,&nbsp;David A. Gudis,&nbsp;Davangere P. Devanand,&nbsp;Jonathan B. Overdevest","doi":"10.1002/alr.70149","DOIUrl":"10.1002/alr.70149","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Persistent COVID-associated olfactory dysfunction (C19OD) negatively impacts quality of life (QoL). This prospective longitudinal cohort study sought to determine which aspects of chemosensory recovery may preferentially influence QoL improvement in this population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Individuals with C19OD (<i>N</i> = 100) completed chemosensory and QoL assessment with Sniffin’ Sticks, Taste Assessment, Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS), and QOD-PAR at baseline and 1 year. Multivariable analyses assessed baseline and longitudinal associations between chemosensory dysfunction and QOD-NS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>QoL associated with TDI (Coef.; [CI]; <i>p</i>-value: −0.32; [−0.62, −0.032]; 0.030), threshold (−0.82; [−1.5, −0.14]; 0.019), QOD-Par (−1.0; [−0.20, −1.9]; 0.016), and self-reported gustatory dysfunction (GD) (−7.4; [−14, −0.46]; 0.037) at baseline assessment, though quantitative GD did not associate with QoL. Longitudinally, improvements in discrimination (−1.2; [−2.3, −0.18]; 0.023) and QOD-Par (−2.5; [−0.99, −4.1]; 0.002) scores were associated with improved QoL. Individuals with improved parosmia symptoms experienced a 12.86 (12.99, 0.040) QOD-NS point improvement from baseline compared to 5.91 (7.98, &lt; 0.001) for those with persistent parosmia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Independent of mental health, chemosensory function independently drives QoL in C19OD. Parosmia, low odor threshold, and patient-reported GD are all associated with poorer QoL at baseline. Longitudinally, the ability to differentiate among odors is an important correlate of improvement of smell-related QoL in C19OD patients, while parosmia is the strongest driver of longitudinal recovery of smell-related QoL in C19OD. Trending domain-specific olfactory performance in C19OD may allow for improved patient counseling and QoL prognosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"968-976"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Steroid Use and Asthma Comorbidity in Central Compartment Atopic Disease: The Predictive Role of Olfactory Dysfunction and Eosinophilia","authors":"Lin Hsu,&nbsp;Chia-Chen Wu,&nbsp;Hsiang-Sheng Wang,&nbsp;Chien-Cheng Chen,&nbsp;Ta-Jen Lee,&nbsp;Po-Hung Chang,&nbsp;Yi-Wei Chen,&nbsp;Yu-Ning Tsao,&nbsp;Hsiang-An Hsueh,&nbsp;Ya-Cheng Tang,&nbsp;Chia-Hsiang Fu","doi":"10.1002/alr.70147","DOIUrl":"10.1002/alr.70147","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Central compartment atopic disease (CCAD) is a distinct phenotype of chronic rhinosinusitis with nasal polyps (CRSwNP), characterized by central nasal cavity inflammation. Although well described in Western populations, data from East Asia remain limited. We aimed to characterize CCAD's clinical features, identify predictors of postoperative oral corticosteroid (OCS) use, and explore CCAD's association with comorbid asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this propensity score-matched case-control study, patients with bilateral CRSwNP were classified as CCAD or non-CCAD using endoscopic findings. Clinical characteristics, laboratory markers, and surgical outcomes were compared. Subgroup analysis within CCAD evaluated predictors of postoperative OCS use and comorbid asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with non-CCAD CRSwNP, CCAD patients had more severe subjective olfactory dysfunction (<i>p</i> = 0.035) and a distinct allergic inflammatory profile, including higher blood and tissue eosinophils, serum immunoglobulin E, and eosinophil cationic protein. Within the CCAD cohort, patients requiring postoperative OCS use had greater tissue eosinophilia; a threshold of ≥ 21 cells/high-power field independently predicted OCS need (hazard ratio = 12.4, 95% confidence interval = 1.6–93.4, <i>p</i> = 0.015). Comorbid asthma was associated with higher Lund–Mackay scores and blood eosinophilia (<i>p</i> = 0.012 and <i>p</i> = 0.007, respectively).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CCAD is associated with greater subjective olfactory dysfunction and a distinct allergic inflammatory profile. Tissue eosinophilia independently predicts postoperative corticosteroid use, while advanced disease and elevated blood eosinophils predict comorbid asthma. These findings support risk stratification and personalized postoperative management in CCAD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"977-985"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Utilization of the Completeness of Surgery Index in Revision Endoscopic Sinus Surgery Patients on Biologic Therapy for CRSwNP","authors":"Isha Thapar,&nbsp;Margaret B. Mitchell,&nbsp;Saawan D. Patel,&nbsp;Vidit Talati,&nbsp;Jennifer E. Douglas,&nbsp;Michael A. Kohanski,&nbsp;Eric H. Holbrook,&nbsp;Stacey T. Gray,&nbsp;Benjamin S. Bleier,&nbsp;Nithin D. Adappa,&nbsp;James N. Palmer,&nbsp;Alan D. Workman","doi":"10.1002/alr.70219","DOIUrl":"10.1002/alr.70219","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key Points</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>Revision surgery in patients on biologic therapy with lower preoperative CoSI scores (&lt;70, reflecting previously incomplete surgery) resulted in significantly greater improvement in SNOT-22 after revision surgery compared to patients with previously adequate surgery.</li>\u0000 \u0000 <li>Incomplete prior surgery, as assessed by the CoSI, remains a likely correctable contributor to symptomatology even in patients receiving biologics.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"1031-1033"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reverse Septal Flap Necrosis in Endoscopic Skull Base Reconstruction","authors":"Nana-Hawwa Abdul-Rahman,&nbsp;Aileen Cui,&nbsp;Garret Choby,&nbsp;Eric W. Wang,&nbsp;Georgios A. Zenonos,&nbsp;Paul A. Gardner,&nbsp;Carl H. Snyderman","doi":"10.1002/alr.70236","DOIUrl":"10.1002/alr.70236","url":null,"abstract":"&lt;p&gt;The pedicled nasal septal flap (NSF) revolutionized endoscopic skull base reconstruction by reducing cerebrospinal fluid (CSF) leak rates. Despite its success, NSF harvest leaves a large donor site on the septal cartilage to heal by secondary intention, contributing to postoperative nasal morbidity [&lt;span&gt;1&lt;/span&gt;]. The reverse septal flap (RSF) was developed as a secondary flap to cover the exposed septal cartilage, reducing crusting, improving nasal air flow, and minimizing nasal deformities [&lt;span&gt;2&lt;/span&gt;]. While the benefits of RSF are well documented, the incidence and risk factors for RSF necrosis have not been systematically studied. The present study aims to evaluate the incidence of RSF necrosis following endoscopic endonasal surgery (EES) and identify associated clinical and operative factors.&lt;/p&gt;&lt;p&gt;In this prospective cohort study, 135 patients (with a subset of 29 having complete intraoperative data) underwent EES with NSF and RSF reconstruction between August 2024 and March 2025 at a tertiary academic center. The primary outcome was RSF necrosis, defined by postoperative clinical exam showing epithelial necrosis with tissue loss and exposed perichondrium/cartilage or adherent crust. Covariates include preoperative clinicodemographic variables, intraoperative factors, and postoperative outcomes. Statistical analyses were conducted using STATA, version 18 (StataCorps, College Station, TX, USA), with alpha set at 0.05.&lt;/p&gt;&lt;p&gt;Of the 135 patients (median age 55 years, 46% females), RSF necrosis occurred in five participants (3.7%) (Table 1). RSF necrosis was managed with partial debridement in clinic and topical application of antibiotic ointment until healing was complete. Necrosis was associated with prolonged healing time (5/5, vs. 6/124, &lt;i&gt;p&lt;/i&gt; &lt; 0.001). Of the 29 patients with intraoperative data (Table 2), patients who developed RSF necrosis (n = 4) had shorter flap length (median: 2.5 cm [IQR: 2.5–2.5] vs. 3.0 cm [IQR: 2.5-3], &lt;i&gt;p&lt;/i&gt; = 0.026). RSF necrosis occurred only in meningioma (2/20) and “other” pathology (3/49), whereas no RSF necrosis was seen in pituitary tumors or chordoma cases (0/66) (&lt;i&gt;p&lt;/i&gt; = 0.028). Surgical approach (transcribiform vs. all other surgical approaches) was not associated with NSF necrosis. No significant differences were observed in age, sex, BMI, smoking status, major comorbidities, previous sinus surgery or EES, protective nasal sleeve use, RSF vascularity (indocyanine green dye fluorescence), duration of surgery, length of stay, postoperative complications, and ED-visits or readmission between those with and without RSF necrosis (&lt;i&gt;p&lt;/i&gt; &gt; 0.05).&lt;/p&gt;&lt;p&gt;Only 29 of 135 patients had complete data for the flap-length subgroup analysis, and key measurements were absent in several cases. Because flap lengths were not documented in the remaining 105 patients, this introduces a high standard error around the flap-length estimate and raises the possibility of selection bias; thus, these resu","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"1053-1055"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergic Rhinitis Amplifies Asthma Risk in Patients With Chronic Rhinosinusitis: A Large-Scale Retrospective Cohort Analysis","authors":"Austin J. Lee,&nbsp;Mohamad R. Chaaban","doi":"10.1002/alr.70141","DOIUrl":"10.1002/alr.70141","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) are two highly prevalent airway diseases in the United States. While the coexistence of CRS and asthma is well recognized, less is known about the development of new-onset asthma in CRS, particularly in the context of comorbid AR. This study assessed the impact of CRS and AR on incident asthma using a large electronic health record (EHR) database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort study using the TriNetX US Collaborative Network, a federated EHR platform encompassing over 100 million patients. Adults ≥ 18 years between January 2009 and December 2019 with CRS were compared to controls without CRS. A second analysis compared patients with CRS and concurrent AR to those with CRS alone. Supplemental analyses substituted chronic rhinosinusitis with nasal polyps (CRSwNP) for CRS. Propensity score matching balanced cohorts on demographics and comorbidities. Primary outcomes were new-onset asthma and asthma exacerbations, assessed at 1, 2, and 5 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After matching, pre-existing CRS was associated with higher risk of new-onset asthma (adjusted relative risk [aRR] = 1.42, 95% CI 1.36–1.48) and exacerbations (aRR = 1.87, 95% CI 1.75–2.00) at 1 year versus CRS controls, with similar trends at 2 and 5 years. Coexisting AR further amplified risk: patients with CRS + AR had increased asthma incidence relative to CRS alone at 1 year (aRR = 1.69, 95% CI 1.65–1.73), 2 years (aRR = 1.65, 95% CI 1.62–1.68), and 5 years (aRR = 1.58, 95% CI 1.56–1.60), with more than doubled exacerbation risk across all time points. Directionally similar findings were observed in CRSwNP analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CRS is associated with increased risk of incident asthma and subsequent exacerbations, and coexisting AR identifies a higher-risk phenotype within CRS. These findings highlight the need for phenotype-informed studies to determine whether targeted upper-airway management can mitigate downstream asthma burden.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"931-941"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147456950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parosmia Beyond Olfactory Loss: A Propensity Score-Matched Study of Central Sensitization-Associated Comorbidities","authors":"Elay Amidor,&nbsp;Nidal Muhanna,&nbsp;Avraham Abergel,&nbsp;Narin-Nard Carmel Neiderman,&nbsp;David Rosen,&nbsp;Gurston Nyquist,&nbsp;Emma Anisman,&nbsp;Udi Shapira,&nbsp;Hen Chaushu","doi":"10.1002/alr.70222","DOIUrl":"10.1002/alr.70222","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key Points</h3>\u0000 \u0000 <div>\u0000 <ul>\u0000 \u0000 <li>Parosmia is linked to migraine, chronic pain, fibromyalgia, and hypersomnia beyond anosmia.</li>\u0000 \u0000 <li>Central sensitization comorbidities distinguish parosmia from quantitative olfactory loss.</li>\u0000 \u0000 <li>Findings support parosmia as a disorder of altered central sensory processing.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":13716,"journal":{"name":"International Forum of Allergy & Rhinology","volume":"16 9","pages":"1039-1042"},"PeriodicalIF":4.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}